Venclexta/rituximab (venetoclax/rituximab)

pCPA File Number: 21136

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic lymphocytic leukemia (CLL), previously untreated, in adult patients who are fludarabine ineligible (in combination with obinutuzumab)

Sponsor/Manufacturer:

AbbVie Corporation

CDA-AMC Project Number:

PC0162-000

pCPA Engagement Letter Issued:

2019-06-26

Negotiation Process Concluded:

2019-10-28